Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
QuantumPharm, Inc. ( (HK:2228) ) has shared an announcement.
XtalPi Holdings Limited has scheduled a board meeting for 25 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and to authorize their publication. The board will also consider the payment of a final dividend, if any, and handle other corporate matters, signaling an upcoming disclosure of financial performance and potential shareholder returns.
The meeting date sets a timeline for investors and stakeholders to anticipate the company’s full-year financial update and any decisions on capital distribution. The announcement underscores standard governance and reporting practices, and may influence market expectations around XtalPi’s profitability, cash position, and commitment to rewarding shareholders through possible dividends.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a Cayman Islands-incorporated company listed on the Stock Exchange of Hong Kong under stock code 2228. The group operates through its subsidiaries and is overseen by a board comprising executive and independent non-executive directors, reflecting a typical governance structure for a publicly traded firm in the region.
Average Trading Volume: 70,081,788
Technical Sentiment Signal: Buy
Current Market Cap: HK$41.98B
See more insights into 2228 stock on TipRanks’ Stock Analysis page.